Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Thermo Fisher Scientific from “hold” to “buy.” Overall analyst sentiment is “Moderate Buy,” with a consensus price target of $628.78.
• Thermo Fisher reported quarterly adjusted earnings of $6.03 per share, exceeding estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion.
• Insiders sold 73,768 shares worth approximately $44.1 million during the last quarter, while institutional investors own 89.23% of the company.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other analysts have also weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective on the stock. Scotiabank assumed coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an "outperform" rating on the stock. Jefferies Financial Group reiterated a "buy" rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Weiss Ratings raised Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 28th. Finally, Wells Fargo & Company downgraded Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a research report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $628.78.

Thermo Fisher Scientific Stock Up 0.5%

Shares of TMO opened at $655.49 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business has a fifty day moving average of $618.62 and a 200 day moving average of $534.71. The company has a market cap of $242.37 billion, a PE ratio of 35.26, a P/E/G ratio of 2.73 and a beta of 0.87. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $683.63.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 earnings per share. The business's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently modified their holdings of TMO. Bank OZK purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $1,096,000. Ausdal Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $456,000. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. German American Bancorp Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $4,920,000. Finally, Parallax Volatility Advisers L.P. bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $814,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.